These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12413866)

  • 41. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling.
    Ooms F; Wouters J; Oscari O; Happaerts T; Bouchard G; Carrupt PA; Testa B; Lambert DM
    J Med Chem; 2002 Apr; 45(9):1748-56. PubMed ID: 11960486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel class of potent tetrahydrocannabinols (THCS): 2'-yne-delta 8- and delta 9-THCS.
    Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
    Life Sci; 1995; 56(23-24):2013-20. PubMed ID: 7776826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
    Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
    J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract.
    Casu MA; Porcella A; Ruiu S; Saba P; Marchese G; Carai MA; Reali R; Gessa GL; Pani L
    Eur J Pharmacol; 2003 Jan; 459(1):97-105. PubMed ID: 12505538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
    Anikwue R; Huffman JW; Martin ZL; Welch SP
    J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
    Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
    J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
    Wiley JL; Jefferson RG; Grier MC; Mahadevan A; Razdan RK; Martin BR
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1013-22. PubMed ID: 11181936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach.
    Adami M; Frati P; Bertini S; Kulkarni-Narla A; Brown DR; de Caro G; Coruzzi G; Soldani G
    Br J Pharmacol; 2002 Apr; 135(7):1598-606. PubMed ID: 11934799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
    Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
    Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding.
    Aung MM; Griffin G; Huffman JW; Wu M; Keel C; Yang B; Showalter VM; Abood ME; Martin BR
    Drug Alcohol Depend; 2000 Aug; 60(2):133-40. PubMed ID: 10940540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
    Huffman JW; Yu S; Showalter V; Abood ME; Wiley JL; Compton DR; Martin BR; Bramblett RD; Reggio PH
    J Med Chem; 1996 Sep; 39(20):3875-7. PubMed ID: 8831752
    [No Abstract]   [Full Text] [Related]  

  • 52. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
    Massi P; Fuzio D; Viganò D; Sacerdote P; Parolaro D
    Eur J Pharmacol; 2000 Jan; 387(3):343-7. PubMed ID: 10650181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
    Huffman JW; Padgett LW; Isherwood ML; Wiley JL; Martin BR
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5432-5. PubMed ID: 16889960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
    Dar MS
    Brain Res; 2000 May; 864(2):186-94. PubMed ID: 10802025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
    Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
    J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA; Járai Z; Bátkai S; Kunos G
    Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    Haller VL; Cichewicz DL; Welch SP
    Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA
    Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
    Klegeris A; Bissonnette CJ; McGeer PL
    Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.